Sarah Cannon Research Institute to Present New Trial Results at San Antonio Breast Cancer Symposium
NASHVILLE, Tenn.--(BUSINESS WIRE)--Dec 10, 2008 - Sarah Cannon Research Institute (SCRI) investigators will present the latest results of five of its breast cancer trials during the San Antonio Breast Cancer Symposium, which takes place today through Dec. 14.
Denise A. Yardley, M.D., SCRI's director of breast cancer research, will present her research on various treatments—chemotherapy, anti-angiogenesis agents and targeted therapies—at four poster sessions on Dec. 12 and 13. Anti-angiogenesis drugs inhibit the growth of blood vessels that feed tumors, while targeted therapies deliver treatment directly to cancer cells and limit damage to surrounding healthy tissue.
The largest trial Dr. Yardley is presenting, with an enrollment of 214 patients, focuses on a combination treatment of the anti-angiogenesis agent Avastin with the chemotherapy drug Taxotere for the adjuvant treatment of early-stage breast cancer. Data for the first 138 patients enrolled indicate the combination treatment is reasonably well-tolerated and without unexpected side effects.
“Physicians are learning that breast cancer comes in a variety of forms, and some types respond to certain treatments better than others,” Dr. Yardley said. “We want to determine whether targeted drugs can be used alone or with chemotherapy to improve treatment results while reducing the side effects caused by damage to healthy cells.”
Dr. Yardley's other three presentations focus on a pre-breast surgery combination treatment (Abraxane with Gemzar and Ellence) for patients with locally advanced disease; an anti-angiogenic treatment of Avastin combined with hormonal therapies consisting of either Arimidex or Faslodex; and the drug Javlor by itself and in combination with Herceptin.
The symposium also accepted an abstract from David Spigel, M.D., SCRI's director of lung cancer research, on a pilot study of a combination treatment that includes the anti-angiogenesis oral drug Nexavar for the adjuvant treatment of high-risk, early-stage breast cancer.
Also this month SCRI is embarking on the 1,800-patient TITAN trial (Trial of Ixempra vs. Taxol in Adjuvant Therapy of Triple Negative Breast Cancer), a randomized, phase III study investigating the role of Ixempra in the adjuvant treatment of early breast cancer.
SCRI is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of nearly 500 physicians in 24 states. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.
Contact: Sarah Cannon Research Institute
Anna Walker, 615-329-7216
Posted: December 2008